Comparing the current results to its competitors, Biostax reported Revenue decrease in the 3 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 10.69 %, recorded in the same quarter.
Biostax Corp, slower than the average decrease reported by the company's competitors of -44 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -44 %
Biostax's Comment on Competition and Industry Peers
The company's sublicensees operate in a highly competitive and rapidly evolving human treatment industry. They face competition from large pharmaceutical and biotechnology firms, specialty pharmaceutical and generic drug companies, academic institutions, government agencies, and research organizations. Many competitors possess greater financial, technical, and human resources, along with more experience in product discovery, development, regulatory approval, and commercialization. Competitors may obtain FDA approval and market acceptance more effectively, which could render the sublicensees' products obsolete or non-competitive. Additionally, the development of new treatment methods may affect competitiveness. The sublicensees' ability to address these competitive challenges will significantly influence the value of the company's equity holdings in them.
Azitra Inc is a company that operates on a business model focused on developing and commercializing microbiome-based therapeutics for various skin conditions. It aims to use the potential of the human skin microbiome to develop innovative and effective treatments.
Biohaven Ltd operates as a pharmaceutical company that focuses on discovering and developing therapies for neurological diseases and rare disorders. Their business model revolves around conducting extensive research and clinical trials to bring innovative treatments to market. By collaborating with healthcare professionals, regulatory agencies, and investors, Biohaven aims to improve the lives of patients suffering from these conditions and provide a significant return on investment for stakeholders.
Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.
TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.
Sources:
Biostax Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biostax Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
